Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

AVIDITY BIOSCIENCES INC (RNA)

343 + Investors. Track Smart Money conviction in RNA. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +67
Streak
2Q ▲
Buyers last Q
58%

Smart Money Signals — RNA

Based on 322 hedge funds · latest filing: 2025 Q4 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added RNA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
322 hedge funds hold RNA right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +43% more funds vs a year ago

fund count last 6Q
+97 new funds entered over the past year (+43% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 58% buying

219 buying161 selling
Last quarter: 219 funds bought or added vs 161 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+64 vs last Q)

new funds entering per quarter
Funds opening a new RNA position: 37 → 25 → 79 → 143. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
📌

Mixed — 29% long-term, 47% new

29% conviction (2yr+) 25% medium 47% new
Of the 322 current holders: 92 (29%) held >2 years, 79 held 1–2 years, and 151 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💰

Price up while funds trimmed (+57% value, -11% shares)

Value
+56%
Shares
-11%
Last quarter: total value of institutional RNA holdings rose +57% even though funds reduced share count by 11%. The stock price increased enough to offset the selling. Institutions are quietly trimming into price strength — watch for rotation.
🚀

Acceleration phase — new buyers rushing in

50 → 37 → 25 → 79 → 143 new funds/Q
New funds entering each quarter: 37 → 25 → 79 → 143. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
📊

Mixed cohorts — 39% veterans, 47% new entrants

39% veterans 15% 1-2yr 47% new
Of 343 current holders: 133 (39%) held 2+ years, 50 held 1–2 years, 160 (47%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

Strong quality — 33% AUM from major funds

33% from top-100 AUM funds
42 of 322 holders rank in the top 100 by AUM, accounting for 33% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.9
out of 10
Moderate Exit Risk
Exit risk score 4.9/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Hedge Fund Ownership: RNA

How many hedge funds hold RNA — quarterly history vs. share price
Quarterly hedge fund ownership of RNA vs. share price

Market Analysis: RNA

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: RNA

-- --
Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

19 top-rated funds 11 high-conviction
Consensus
5.6
/ 10
breadth
×
Elite
3.8
/ 10
conviction
Hedge Fund Positioning: RNA
2026 Q1 Stats Unlock in 17 days 343 + Investors

Track Smart Money conviction in RNA. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2025 Q4) Prior (2025 Q3) Change
Funds Holding 343 273 25.64%
13F Shares 144M 162M -11.08%
Total Value $10.40B $6.64B 56.53%
New Positions 150 86 +64
Increased Positions 98 133 -35
Closed Positions 80 20 +60
Reduced Positions 99 61 +38
Total Calls 8 12 -33.33%
Total Puts 16 12 33.33%
PUT/CALL Ratio 2.0 1.0 Bearish

Statistics: RNA

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

343 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in RNA. Verified SEC 13F-HR filings.

Top 4 institutional holders of RNA — 2025 Q4 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 BLUEFIN CAPITAL MANAGEMENT, LLC 0.18% 10,000 $721K
2 SUMMIT SECURITIES GROUP LLC 0.07% 41,200 $551K
3 Marex Group plc 0.01% 9,900 $404K
4 AlphaQuest LLC 0.01% 1,450 $105K
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — AVIDITY BIOSCIENCES INC (RNA)

What does the Smart Money Trend signal show for RNA?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added RNA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for RNA?

Slight buying edge — 58% buying: Last quarter: 219 funds bought or added vs 161 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for RNA holders?

Strong quality — 33% AUM from major funds: 42 of 322 holders rank in the top 100 by AUM, accounting for 33% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held RNA?

Mixed — 29% long-term, 47% new: Of the 322 current holders: 92 (29%) held >2 years, 79 held 1–2 years, and 151 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.